Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CM 4612

Drug Profile

CM 4612

Alternative Names: CM-4612; CM-ADHD; CM-AT; CM-PK

Latest Information Update: 04 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureMark LLC
  • Developer Curemark
  • Class Enzymes
  • Mechanism of Action Enzyme modulators; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Autistic disorder
  • No development reported Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA (PO, Powder)
  • 28 Mar 2018 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
  • 22 Dec 2017 Curemark completes the phase III Blum study for Autistic disorders (In children) in USA (PO) (NCT02410902)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top